BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 20
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• 

  Weight loss

  Viking to Accelerate Development of Obesity Drug With Two Q4 Catalysts

  Following an end-of-Phase II meeting with the FDA in the fourth quarter, Viking Therapeutics plans to push its subcutaneous obesity therapy VK2735 into late-stage development and to start a Phase II trial for an oral formulation.

  October 24, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Steady But Slow: Future Outlook For Investment

  In this episode of Denatured, Lori and guests from Teva Pharmaceuticals and TOWER Capital review the investment landscape this year and the policies influencing investment heading into 2025.

  October 24, 2024

   · 

  1 min read

   · 

  Lori Ellis
• 

  Diabetes

  GLP-1 Prescriptions for Type 1 Diabetes Spike Despite Lack of FDA Approval: Study

  While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has sharply increased, according to researchers, who warn about the risk of serious side effects such as ketoacidosis.

  October 24, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  GLP-1

  Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study

  Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.

  October 24, 2024

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Gene therapy

  Roche Inks Potential $1B Gene Therapy Deal With Dyno, Eyes Neurological Diseases

  With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy delivery technology, which synthesizes virus capsids with better functionality and manufacturability.

  October 24, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Job Creations

  Massachusetts Tax Incentives for Moderna, Vertex and More Creating 1,155 Jobs

  Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in Massachusetts. Moderna and Vertex received the largest awards and will add over 600 combined jobs.

  October 24, 2024

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Editorial

  Why It’s OK to Talk About Catalent’s Pending Buyout by ‘Novo’

  The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo Nordisk Foundation, one of the world’s largest charitable foundations.

  October 24, 2024

   · 

  6 min read

   · 

  Jef Akst
• 

  Vaccines

  CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64

  The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

  October 24, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Business

  Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024

  October 24, 2024

   · 

  1 min read
• Business

  ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025

  October 24, 2024

   · 

  17 min read